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Long-Term Clinical Outcomes For Primary Angioplasty with Resolute
Zotarolimus Eluting Stent in ST-Segment Elevation Acute Myocardial Infarction
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Background: Historically bare metal stents were considered standard of care for ST-
segment elevation acute myocardial infarction (STEMI). There is limited data on
STEMI patients treated for primary angioplasty with ResoluteTM zotarolimus-eluting
stent (R-ZES) and the everolimus-eluting stent (EES).
Methods: The global RESOLUTE program enrolled STEMI patients in 4 trials:
RESOLUTE-All Comers (RAC), RESOLUTE International, RESOLUTE China, and
RESOLUTE China Registry. The multicenter R-AC trial randomized patients to R-
ZES vs. EES. STEMI was a prespeciﬁed subset analysis. Target Lesion Failure (TLF)
was deﬁned as a composite of death from cardiac causes (CD), target vessel
myocardial infarction (TV-MI), and target lesion revascularization (TLR). Stent
thrombosis (ST) was deﬁned as ARC deﬁnite/probable ST.
Results: Among 7618 patients who received R-ZES in the pooled RESOLUTE clinical
program, 854 had STEMI. Mean age was 5912 years, 81% of patients were men, 23%
had diabetes mellitus, and patients had on average 1.40.7 lesions treated. The 4-year
Kaplan-Meier incidence of TLF was 11.5%, TLR 4.8%, CD/TV-MI 8.2%, CD 5.5%,
TV-MI 2.7%, and ST 1.9%. Among the 2292 patients randomized in R-AC, 122 STEMI
patients were treated with R-ZES and 158 with EES. There were no signiﬁcant dif-
ferences at 5 years in TLF, TLR, CD, TV-MI, or ST, but there was a signiﬁcant
reduction in all cause death / TV-MI with R-ZES (5.1% vs 9.0%, p¼0.036) (Table).
Conclusions: A pooled analysis of complex STEMI patients treated with R-ZES
found R-ZES to be associated with excellent and sustained clinical outcomes. Addi-
tionally, long-term outcomes with R-ZES in STEMI patients were numerically lower
than or similar to EES; however, R-ZES had a signiﬁcant reduction in all cause death/
TV-MI as compared to EES at 5 years. Submitted on behalf of the RESOLUTE Global
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Target Lesion Failure, % (n) 7.6% (9) 10.3% (16) 0.528
Target Lesion Revascularization, % (n) 2.5% (3) 1.9% (3) 1.00
All cause death 5.1% (6) 12.3% (19) 0.055
Cardiac death 3.4% (4) 5.8% (9) 0.404
Non cardiac death 1.7% (2) 6.5% (10) 0.075
CD/TV-MI, % (n) 5.1% (6) 9.0% (14) 0.248
All cause death/TV-MI 6.8% (8) 15.5% (24) 0.036
ARC Deﬁnite/Probable Stent Thrombosis, %
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0.8% (1) 1.3% (2) 1.00TCT-25
A Real-World Single Centre Experience Using The Self–Expanding
Coronary Stent
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Background: A coronary self-expanding stent (Stentys S.A., Paris, France) may
overcome the drawback of difﬁcult stent sizing and avoid stent malapposition with
consequent risk of restenosis and thrombosis. This feature should be particularly
useful in case of primary percutaneous coronary interventions (PCI) in patients with
ST-elevation myocardial infarction (STEMI) or in the presence of complex coronary
anatomy like coronary ectasia (a segment of artery > 1.5 times the diameter of
adjacent segments) or bifurcations.
Methods: We tasted the efﬁcacy and safety of this stent in consecutive patients un-
dergoing PCI in our centre. The decision to use a self-expanding stent was at
discretion of the operator. The primary endpoint was the composite of the following
major adverse cardiac and cerebrovascular events (MACCE) at 12 months: death,
recurrence of myocardial infarction, target vessel revascularization (TVR) and stroke.
Results: 82 patients (mean age: 64 +/-15; men: 83%; diabetes: 22%) treated with a self-
expanding stent were enrolled. The indications for PCI were STEMI in 62%, non ST-
elevationmyocardial infarction (NSTEMI)/unstable angina in 21%, and stable angina in
17%. 40%of patients had ectatic coronary arteries (with a vessel diameter> 4.5mm) and
18% coronary bifurcated lesions. DES/BMS ratio was 56/26. Two patients (2.4%)
experienced MACCE at 12 months. In both of them a geographic miss during stent
deployment with non complete coverage of the lesion leads to TVR after few months.
Conclusions: The self-expanding stent showed a low rate of clinical events in routine
clinical practice. This stent is particularly useful in case of difﬁcult stent sizing like
STEMI, coronary ectasia or bifurcations. Self-expanding stent deployment is different
compared to the traditional stents and a learning curve is needed in order to avoid
geographic miss and achieve a good result of the procedure.B8 JACC Vol 64/11/Suppl B jTCT-26
Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in
patients undergoing primary percutaneous coronary intervention: 5 year
follow-up from the COMPARE I trial
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Background: Long-term all-comers data of the current generation everolimus-eluting
stent (Xience V, Abbott Vascular, Santa Clara, CA, USA) compared to the ﬁrst
generation paclitaxel-eluting stent (Taxus Liberté, Boston Scientiﬁc, Natick, MA,
USA; PES) in patients undergoing primary percutaneous coronary intervention (PCI)
for ST-elevating myocardial infarction (STEMI) are scarce.
Methods: The COMPARE I study was a prospective, randomized, single-center, all-
comers trial randomly allocatingpatients to receive either EESorPES (1:1). It is to date the
only randomized trial comparing EES to PES in a true all-comers population with an in-
dependent adjudicated 5-year follow-up.Weperformed a post-hoc sub-analysis in patients
treated with primary PCI. The pre-speciﬁed endpoint was major adverse cardiovascular
events (MACE) deﬁned as the composite of the safety endpoints death or myocardial
infarction (MI) and the efﬁcacy endpoint target vessel revascularization (TVR).
Results: Of the 1800 study patients, 452 patients underwent primary PCI for STEMI
(25.1%) of whom 240 were treated with EES and 212 with PES. At 5 years EES was
superior to the PES with a signiﬁcant lower incidence of the endpoints MACE and
TVR. Moreover, EES showed a trend for reduction in MI and target lesion revascu-
larization. No signiﬁcant differences were found in rates of death and deﬁnite/probable
stent thrombosis. The 5 year outcomes are tabulated.Conclusions: At 5-years EES reduced signiﬁcantly MACE in patients treated with
primary PCI for STEMI compared to PES which was mainly driven by lower rates of
TVR.
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Background: Biocompatible durable polymer coatings for drug-eluting stents (DES)
were developed to reduce the risk of stent thrombosis, which is generally increased in
the setting of acute myocardial infarction (MI). These coatings are used on novel,
ﬂexible, and highly deliverable third-generation DES, investigated in the randomized,
multicenter, all-comer DUTCH PEERS (TWENTE II) trial. Of the 1,811 eligible all-
comer patients of DUTCH PEERS, 817 (45%) were treated in the setting of acute MI.
Methods: We assessed the one-year safety and efﬁcacy of the Resolute Integrity
zotarolimus-eluting stent (ZES) (Medtronic, Santa Rosa, CA, USA) and Promus
Element everolimus-eluting stent (EES) (Boston Scientiﬁc, Natick, MA, USA) in 817
DUTCH PEERS patients who were treated for acute MI. One-year follow-up data ofSeptember 13–17, 2014 j TCT Abstracts/Acute Myocardial Infarction
Table. Independent Predictors of 3-year Cardiac Mortality
Hazard
ratio
95% Conﬁdence
Interval P Value
Peak CK-MB ratio (per 100
ULN)
1.13 1.04 to 1.22 0.002
Age (per 5 years) 1.20 1.09 to 1.31 0.0001
Diabetes mellitus 2.18 1.42 to 3.33 <0.001
Culprit lesion of proximal LAD 1.62 0.95 to 2.76 0.08
PCI of left main artery 4.19 1.67 to 10.53 0.002
Killip class 2-4 2.45 1.51 to 3.97 <0.001
Baseline creatinine (per 0.1
mg/dL)
1.05 1.03 to 1.07 <0.001
Bivalirudin use (vs. UFH+GPI) 0.47 0.31 to 0.72 <0.001
Acquired thrombocytopenia 1.84 1.19 to 2.87 0.007
Major bleeding 2.53 1.56 to 4.11 <0.001
PCI¼percutaneous coronary intervention; UFH¼unfractionated heparin; GPI¼glycoprotein IIb/
IIIa inhibitor.
www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMall patients were obtained; adverse events were externally adjudicated by an inde-
pendent committee. The primary endpoint was target vessel failure (TVF) at 1-year, a
composite of cardiac death, target vessel related MI, and clinically indicated target
vessel revascularization. Secondary endpoints included all the individual components
of the primary endpoint, the incidence of stent thrombosis (ST), and the patient-ori-
ented clinical endpoint (POCE).
Results: Patient and lesion characteristics did not differ between groups with the only
exception being higher proportions of severely calciﬁed lesions (87/548(16%) vs. 108/
500(22%), p¼0.02) and stent postdilatation in EES (402/548 (73%) vs. 400/500
(80%), p¼0.01). At one year, TVF did not differ signiﬁcantly between the two stent
arms (20/421(5%) vs. 15/396 (4%, p¼0.50). In addition, POCE was 8% (32/421) for
ZES and 6% (23/396) for EES (p¼0.31). Deﬁnite-or-probable ST rates were very low
and similar in both groups (2/421 (0.5%) vs. 1/396 (0.3%), p¼1.00).
Conclusions: One-year follow-up of DUTCH PEERS patients, who were treated for
acute MI, demonstrated excellent clinical results with a similar and sustained safety
and efﬁcacy of the Resolute Integrity ZES and the Promus Element EES.
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Background: Primary percutaneous coronary intervention (PPCI) is the treatment of
choice for ST-elevation myocardial infarction (STEMI). The optimum delivery of this
service requires an integrated, multi-disciplinary, consultant-led, protocol-driven
approach. It is widely recognised that resources including availability of medical
personnel are limited during out of working hours, particularly at night. Currently, it is
unclear whether PPCI during working hours is associated with improved outcomes.
Methods:We conducted an observational analysis for 11,461 patients with STEMIwho
underwent PPCI between 2004-2011 at all 8 tertiary cardiac centres in London, UK. The
primary outcome was all-cause mortality at 1 year. We deﬁned working hours as 9am-
5pm (Mon-Fri).We compared outcomes in patients treated out of working hours (OWH)
versus in working hours (IWH). Cox-proportional hazard models built using a stepwise
variable selection process were used to determine independent predictors for mortality.
We used propensity-based matching methods to adjust for measured confounders; and
instrumental variable analyses to adjust for non-measured confounders.
Results: Of the 11,461 patients in the analysis, 7494 patients (65.3%) were treated
with PPCI during OWH. There was no difference in 1-year mortality rates when
comparing OWH vs. IWH (8.6% vs. 7.8%, p¼0.151). Multivariate analysis demon-
strated that PPCI during OWH was not a predictor for 1-year mortality (HR¼1.11,
95%CI: 0.94-1.32, p¼0.201). When stratifying OWH into 2-hourly intervals, multi-
variate analyses demonstrated that there was no particular time interval that was
associated with increased mortality. When analysing 5228 patients in propensity-
matched cohorts, again, PPCI during OWH was not a predictor for 1-year mortality
(HR¼1.10, 95%CI: 0.90-1.34, p¼0.356). Using enrollment year as an instrumental
variable, PPCI during OWH did not affect mortality (absolute difference¼2.1%, 95%
CI:-12.6%,16.8%, p¼0.888).
Conclusions: In this observational analysis of unselected STEMI patients, PPCI
outside routine working hours compared to within routine working hours is safe with
no difference in 1-year mortality.
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CLINICAL AND ANGIOGRAPHIC PROFILE OF PATIENTS
UNDERGOING PRIMARY: DATA FROM FIRST NATIONWIDE REGISTRY
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Background: This brieﬂy describes the set up and the preliminary results of the “ﬁrst
Nationwide” 24/7 Primary PCI for ST-Elevation Myocardial Infarction Program in the
gulf region.
Methods: In our center over 3500 diagnostic and 1500 Interventional PCI, including
Primary PCI procedures were performed in 2013. With this experience, we proceeded
to setup a nationwide Primary PCI program such that all patients with St-Elevation
Myocardial Infarction (STEMI) were referred seamlessly for immediate Primary PCI
through coordination of all Cardiology, Emergency and Ambulance services in theJACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Acwhole country, and under one control and command center. Since its establishment,
we hereby report 422 patients underwent Primary PCI in 6 months. The clinical and
angiographic data were collected and analyzed.
Results: Primary PCI was performed in 422 patients with STEMI (10 months data will
be presented at the conference). Themean age was 50+/-9.5 years. The program allowed
faster and direct transfer of patients to the Primary PCI facility leading very short Door-
to-Balloon Time (DBT) of 52.825 min (>94% of patients were < 90 min). For those
referred from non-Primary PCI facility, 77% had DBT of < 120 min (as stated in the
guidelines)(mean of 8020.7 min). The overall in-hospital mortality for Primary PCI
patients was 2.8%. Radial approach was used in nearly half the patients (43.5%) and
femoral in the other 56.5% with similar DBT for both. More precisely, the time from
arrival to Cath lab to Balloon Dilatation (procedure time) was similar for both ap-
proaches 18.68.3 min for femoral) and (177.2 min for Radial). Overall, less than
TIMI III ﬂow (i.e. TIMI 0, I or II) was found in 85% of patients before Primary PCI, of
these, full TIMI III ﬂow was achieved in 93% of those cases. Achievement of this TIMI
III ﬂow was also similar between Femoral and Radial approaches.
Conclusions: This is the ﬁrst coordinated “Nationwide” Primary PCI program in the
gulf region. The data emphasize how good communication allows Primary PCI for all
STEMI patients, at a very short DBT and with low in-hospital mortality. Radial and
Femoral approaches were used almost equally with similar achievement of TIMI III
ﬂow and procedure time.
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Background: We sought to elucidate: 1) the predictors of enzymatic infarct size
assessed by peak CK-MB in pts with ST-segment elevation myocardial infarction
(STEMI) undergoing primary percutaneous coronary intervention (PCI); and 2) the
impact of peak CK-MB on cardiac mortality at 3 years.
Methods: HORIZONS-AMI was a prospective, open-label, multicenter, dual-arm,
22 factorial randomized trial in pts with STEMI presenting < 12 hours after
symptom onset. The 2 randomization arms consisted of 1) bivalirudin alone vs heparin
plus a glycoprotein IIb/IIIa inhibitor; and 2) TAXUS paclitaxel-eluting stents (PES) vs
bare metal stents (BMS). We evaluated infarct size according to peak CK-MB ratio
(peak-CK-MB/upper limit of normal [ULN]).
Results: Peak CK-MB ratio was available in 3068 of 3345 patients (91.7%). Median
peak CK-MB ratio was 13.9 (IQR 5.8 to 32.4). By linear regression, the independent
predictors of peak CK-MB ratio were US location (p< 0.0001), LAD culprit location
(p< 0.0001), baseline TIMI grade 0/1 ﬂow (p< 0.0001), and post-stent balloon
dilatation (p¼0.04). Beta-blocker use before PCI predicted lower peak CK-MB
(p¼0.03). In a covariate-adjusted Cox regression model, peak CK-MB ratio was an
independent predictor of 3-year cardiac mortality (Table).Conclusions: In this large-scale prospective trial of patients with STEMI undergoing
primary PCI, enzymatic infarct size estimated by peak CK-MB ratio was an inde-
pendent predictor of 3-year cardiac mortality. Further studies are warranted to identify
interventions to reduce infarct size after primary PCI.ute Myocardial Infarction B9
